NCT04607408View on ClinicalTrials.gov

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

July 24, 2024

Study Completion Date

July 24, 2024

Conditions
HIV Infections
Interventions
BIOLOGICAL

CH505TF gp120

HIV-1 CH505 transmitted/founder virus Env gp120 immunogen

BIOLOGICAL

GLA-SE adjuvant

An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)

BIOLOGICAL

Placebo

Sodium Chloride for Injection, 0.9% USP

Trial Locations (1)

1862

Perinatal HIV Research Unit (PHRU), Soweto CRS, Johannesburg

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

HIV Vaccine Trials Network

NETWORK

NCT04607408 - Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants | Biotech Hunter | Biotech Hunter